Table 2.
Previous and follow-up medication
| Treatment | Treatment before the start of JAKi | Treatment at the start of JAKi | Treatment after the start of JAKi |
|---|---|---|---|
| Glucocorticoid | 88 (100%) | 81 (92.0%) | 781 (88.7%) |
| Methylprednisolone pulse | 51 (57.9%) | 18 (20.4%) | 1 (1.1%) |
| Intravenous immunoglobulin | 70 (79.5%) | 34 (38.6%) | 12 (13.6%) |
| Methotrexate | 50 (56.8%) | 46 (52.3%) | 41 (46.6%) |
| Cyclosporin | 37 (42.0%) | 32 (36.4%) | 29 (33.0%) |
| Cyclophosphamide | 9 (10.2%) | 5 (5.7%) | 3 (3.4%) |
| Mycophenolate mofetil | 4 (4.5%) | 2 (2.3%) | 5 (5.7%) |
| Thalidomide | 18 (20.4%) | 14 (15.9%) | 12 (13.6%) |
| Hydroxychloroquine | 22 (25.0%) | 14 (15.9%) | 11 (12.5%) |
| Tocilizumab | 9 (10.2%) | 1 (1.1%) | |
| Infliximab | 1 (1.1%) | ||
| Adalimumab | 1 (1.1%) |